Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06475729 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 498
- Enrollment target
NCT06475729 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 498 participants.
The verdict
NCT06475729, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 498 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to mirikizumab (reference) solution given via autoinjector. Screening is required within 35 days prior to enrollment. For each participant, the total duration for of the clinical trial will be about 15 weeks, including screening.
Interventions
- DRUG Citrate-Free Mirikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2024-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06475729
The ClinicalTrials.gov registry entry for NCT06475729 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 498 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Citrate-Free Mirikizumab is the first listed.
NCT06475729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06475729 about?
NCT06475729 is a clinical study titled "A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants". The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid of it, when given via autoinjector, an injection under the skin, compared to mirikizumab (reference) solution given via autoinjector. Screening is requ...
What is the current status of trial NCT06475729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 498 participants. The study started on 2024-06-24. Estimated completion is 2024-12-27.
What interventions are being tested in trial NCT06475729?
The interventions under investigation include: Citrate-Free Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT06475729?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.